Clinical Trials Directory

Trials / Completed

CompletedNCT03919422

Paravertebral Block for Proximal Humeral Fracture Surgery

Effectiveness of Additional Thoracic Paravertebral Block in Improving Anesthetic Effects of Regional Anesthesia for Proximal Humeral Fracture Surgery in Elderly Patients: Study Protocol for a Randomized Controlled Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
80 (actual)
Sponsor
Shanghai 6th People's Hospital · Academic / Other
Sex
All
Age
65 Years
Healthy volunteers
Not accepted

Summary

This study evaluates the effects of T2 paravertebral block block improving interscalene brachial plexus block and superficial cervical plexus block on the relief of pain intensity during elderly proximal humerus fracture fixation surgery. The brachial plexus and cervical plexus block(IC block) will be performed in half of participants, while the T2 paravertebral block combined with IC block will be performed in the other half.

Conditions

Interventions

TypeNameDescription
PROCEDURET2 paravertebral blockUltrasound guided T2 thoracic paravertebral block is added in ICTP group. After interscalene brachial plexus block and superficial cervical plexus block have been administrated, selective 2nd thoracic nerve root(T2) will be blocked with 10 ml of 0.25% ropivacaine(naropin).
PROCEDUREinterscalene brachial plexus block and superficial cervical plexus blockAn ultrasound-guided IC block using an ultrasound machine (Sonosite, USA), and an linear array probe with a sterile cover and a 22G(Gauge) block needle is performed. An in-plane approach, advancing the needle along the longitudinal axis of the ultrasound transducer and visualizing the entire shaft is employed. Twenty ml of 0.375% ropivacaine(naropin) is injected around brachial plexus and 10 ml of 0.25% ropivacaine around superficial cervical plexus.

Timeline

Start date
2019-05-05
Primary completion
2020-08-25
Completion
2020-08-26
First posted
2019-04-18
Last updated
2021-01-05
Results posted
2021-01-05

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03919422. Inclusion in this directory is not an endorsement.